2016 Medicinal Chemistry Reviews
Case History: Vorapaxar (Zontivity®): A First-In-Clas Protease-Activated Receptor-1 (PAR-1) Antagonist Antiplatelet Agent
Ref. n°: REV2016-ch23
You must be connected to be able to download the pdf file of this chapter.